EA036698B9 - Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif - Google Patents

Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif

Info

Publication number
EA036698B9
EA036698B9 EA201201373A EA201201373A EA036698B9 EA 036698 B9 EA036698 B9 EA 036698B9 EA 201201373 A EA201201373 A EA 201201373A EA 201201373 A EA201201373 A EA 201201373A EA 036698 B9 EA036698 B9 EA 036698B9
Authority
EA
Eurasian Patent Office
Prior art keywords
lif
cancer
subject
fragment
increase
Prior art date
Application number
EA201201373A
Other languages
English (en)
Other versions
EA036698B1 (ru
EA201201373A1 (ru
Inventor
Хоан Сеоане Суарес
Худит Анидо Фольгьера
Андреа Саэс Бордериас
Original Assignee
Фундасио Привада Институт Д'Инвестигасио Онколохика Валь Д'Эброн (Вхио)
Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс (Икреа)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фундасио Привада Институт Д'Инвестигасио Онколохика Валь Д'Эброн (Вхио), Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс (Икреа) filed Critical Фундасио Привада Институт Д'Инвестигасио Онколохика Валь Д'Эброн (Вхио)
Publication of EA201201373A1 publication Critical patent/EA201201373A1/ru
Publication of EA036698B1 publication Critical patent/EA036698B1/ru
Publication of EA036698B9 publication Critical patent/EA036698B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5415—Leukaemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение касается моноклонального антитела или его фрагмента, которое распознает полноразмерный LIF человека, которое продуцируется гибридомной клеточной линией DSM ACC3054, и применения раскрытого антитела или его фрагмента для лечения рака, который характеризуется высоким уровнем LIF или популяцией клеток, экспрессирующих высокие уровни CD 44 и Id1. Изобретение также касается способа in vitro разработки индивидуализированной терапии для пациентов, страдающих заболеваниями, связанными с повышением уровня LIF, способа in vitro отбора пациентов, страдающих раком, связанным с повышением уровня LIF, для лечения таких пациентов с помощью раскрытого антитела или его фрагмента, способа in vitro прогнозирования вероятной продолжительности жизни или вероятности выживания субъектов, страдающих раком, связанным с повышением уровня LIF, и способа in vitro диагностики рака у субъекта или определения предрасположенности субъекта к такому раку или определения стадии или тяжести такого рака у субъекта или мониторинга эффекта терапии, применяемой к субъекту, страдающему таким раком.
EA201201373A 2010-04-05 2011-04-05 Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif EA036698B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10380049A EP2371860A1 (en) 2010-04-05 2010-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
PCT/EP2011/055253 WO2011124566A1 (en) 2010-04-05 2011-04-05 Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation

Publications (3)

Publication Number Publication Date
EA201201373A1 EA201201373A1 (ru) 2013-04-30
EA036698B1 EA036698B1 (ru) 2020-12-09
EA036698B9 true EA036698B9 (ru) 2021-02-25

Family

ID=42338260

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202092276A EA202092276A3 (ru) 2010-04-05 2011-04-05 Антитело, распознающее лейкемический ингибиторный фактор (lif) человека, и применение антител против lif при лечении заболеваний, связанных с нежелательной пролиферацией клеток
EA201201373A EA036698B9 (ru) 2010-04-05 2011-04-05 Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202092276A EA202092276A3 (ru) 2010-04-05 2011-04-05 Антитело, распознающее лейкемический ингибиторный фактор (lif) человека, и применение антител против lif при лечении заболеваний, связанных с нежелательной пролиферацией клеток

Country Status (25)

Country Link
US (3) US8926956B2 (ru)
EP (3) EP2371860A1 (ru)
JP (2) JP6289906B2 (ru)
KR (5) KR20190061098A (ru)
CN (2) CN103797031A (ru)
AU (1) AU2011237922B2 (ru)
BR (1) BR112012025517B1 (ru)
CA (1) CA2797257A1 (ru)
CY (1) CY1119451T1 (ru)
DK (1) DK2556091T3 (ru)
EA (2) EA202092276A3 (ru)
ES (1) ES2608699T3 (ru)
HK (2) HK1208469A1 (ru)
HR (1) HRP20161736T1 (ru)
HU (1) HUE030578T2 (ru)
IL (3) IL222270A (ru)
LT (1) LT2556091T (ru)
MX (2) MX365054B (ru)
PL (1) PL2556091T3 (ru)
PT (1) PT2556091T (ru)
RS (1) RS55539B1 (ru)
SG (1) SG184429A1 (ru)
SI (1) SI2556091T1 (ru)
SM (1) SMT201600468T1 (ru)
WO (1) WO2011124566A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1904093T3 (pl) * 2005-07-19 2018-12-31 Stemgen S.P.A. Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2015040243A2 (en) * 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TWI486172B (zh) * 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
JP7423598B2 (ja) * 2018-04-12 2024-01-29 メドイミューン・リミテッド がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof
MA52300A (fr) * 2018-06-18 2021-04-21 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer
AU2019291305B2 (en) * 2018-06-18 2024-03-21 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Methods for improving response to anti-LIF antibody treatment in individuals with cancer
AU2020354255A1 (en) * 2019-09-29 2022-04-21 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for LIF and use thereof
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
CN111378036B (zh) * 2020-01-09 2021-08-10 北京浩古元方生物医药科技有限公司 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用
CN112294812B (zh) * 2020-11-18 2022-08-16 新乡医学院 一种小分子抑制剂在制备抗肿瘤药物方面的应用
CN114672460B (zh) * 2021-12-21 2023-06-23 中国人民解放军军事科学院军事医学研究院 一种靶向cd44的异质型cic细胞模型的制备方法及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB9004890D0 (en) 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DK0830143T3 (da) * 1995-04-24 2003-06-16 Genentech Inc Anvendelse af leukæmiinhiberende faktor og endothelinantagonister
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005030803A1 (en) 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2010505876A (ja) 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
CN101440128A (zh) * 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
WO2010054499A1 (en) * 2008-11-11 2010-05-20 Telefonaktiebolaget L M Ericsson (Publ) A dpd system with multiple transmitter paths
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TWI486172B (zh) 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥

Also Published As

Publication number Publication date
JP2013523796A (ja) 2013-06-17
EA202092276A2 (ru) 2021-01-29
LT2556091T (lt) 2016-12-27
KR20130121679A (ko) 2013-11-06
US10968273B2 (en) 2021-04-06
HK1180702A1 (zh) 2013-10-25
US20190119373A1 (en) 2019-04-25
KR102294207B1 (ko) 2021-08-26
MX365054B (es) 2019-05-21
CN103797031A (zh) 2014-05-14
US20150139989A1 (en) 2015-05-21
KR20170125137A (ko) 2017-11-13
IL254664B (en) 2022-03-01
CY1119451T1 (el) 2018-03-07
EP2556091A1 (en) 2013-02-13
JP2017019775A (ja) 2017-01-26
JP6289906B2 (ja) 2018-03-07
HRP20161736T1 (hr) 2017-02-10
IL254664A0 (en) 2017-11-30
RS55539B1 (sr) 2017-05-31
EP2556091B1 (en) 2016-09-28
CN109320609A (zh) 2019-02-12
MX2012011636A (es) 2013-04-03
EA202092276A3 (ru) 2021-04-30
PL2556091T3 (pl) 2017-04-28
EA036698B1 (ru) 2020-12-09
US20130142808A1 (en) 2013-06-06
SMT201600468T1 (it) 2017-03-08
WO2011124566A1 (en) 2011-10-13
KR20190061098A (ko) 2019-06-04
IL222270A0 (en) 2012-12-31
EA201201373A1 (ru) 2013-04-30
IL241952A (en) 2017-10-31
BR112012025517A2 (pt) 2017-11-28
AU2011237922A1 (en) 2012-11-01
KR20180078352A (ko) 2018-07-09
EP3045473A1 (en) 2016-07-20
SG184429A1 (en) 2012-11-29
KR20200119344A (ko) 2020-10-19
SI2556091T1 (sl) 2017-02-28
ES2608699T3 (es) 2017-04-12
EP2371860A1 (en) 2011-10-05
HUE030578T2 (en) 2017-06-28
JP6483059B2 (ja) 2019-03-13
HK1208469A1 (en) 2016-03-04
US8926956B2 (en) 2015-01-06
HK1223384A1 (en) 2017-07-28
IL222270A (en) 2016-06-30
DK2556091T3 (en) 2017-01-16
CA2797257A1 (en) 2011-10-13
PT2556091T (pt) 2017-01-03
BR112012025517B1 (pt) 2021-08-31
AU2011237922B2 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
EA036698B9 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
Monneret et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock
WO2019213282A8 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
MX2022000128A (es) Desarrollo de clasificadores para estratificar pacientes.
TW201613637A (en) Methods of treating Alzheimer's Disease
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
MX353186B (es) Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
UA106771C2 (ru) Моноклональные антитела к прогастрину и их применение
CY1118551T1 (el) Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
CO6620013A2 (es) Anticuerpos hacia gdf8 humano
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
Heil et al. Change of aesthetic and functional outcome over time and their relationship to quality of life after breast conserving therapy
MX2024013120A (es) Analisis del transcriptoma para el tratamiento de la inflamacion
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
MX2023001815A (es) Metodos y composiciones de fabricacion de celulas t.
Mortensen et al. Quality of life in patients with multiple myeloma: a qualitative study
ES2671248T3 (es) Métodos para tratar el cáncer que comprenden un guiado por NQO1
EP2539709A4 (en) MORBUS ALZHEIMER SPECIFIC CHANGES OF PROTEIN KINASE C EPSILON (PKC EPSILON) PROTEIN MIRRORS
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
Liu et al. Pathogenesis of acute lung injury in rats with severe acute pancreatitis.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM